NHS, Gilead reach agreement for Yescarta

NHS England said it will cover Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. (NASDAQ:GILD) through the Cancer Drugs Fund (CDF), making Yescarta the first CAR T available

Read the full 270 word article

User Sign In